Second Sight Medical (EYES) IPO Opens Sharply Higher

Today's IPO for Second Sight Medical (NASDAQ: EYES) opened for trading at $17 after pricing 3,500,000 shares of common stock at a price of $9.00 per share, in-line with the expected pricing.

MDB Capital Group, LLC served as the sole underwriter in connection with the offering.

Second Sight develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. Its current product, the Argus® II System, which treats outer retinal degenerations such as retinitis pigmentosa, is the only retinal prosthesis approved in the United States by the FDA and the first approved retinal prosthesis in the world.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• flyExclusive (FLYX) Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K
• Momentus Inc. (MNTS) Receives Nasdaq Deficiency Notice